Back to funds
View filing
Octagon Capital Advisors LP
Updated 6 days agoManaged by Octagon Capital Advisors Lp • Latest filing Q3 2026
Portfolio value
$750.6M
Q3 2026
Filings
4
Quarterly 13F history
Top-10 concentration
98.6%
Weight of largest holdings
Annualized return
—
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 4 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q4 2025 | $823.7M |
| Q1 2026 | $903.6M |
| Q2 2026 | $1.1B |
| Q3 2026 | $750.6M |
Top holdings
26 positions as of Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | $148.5M | 1.69M | 19.79% | — | |
| 2 | $98.3M | 993.0K | 13.10% | — | |
| 3 | $95.6M | 2.51M | 12.73% | — | |
| 4 | $75.2M | 2.35M | 10.02% | — | |
| 5 | $64.8M | 2.14M | 8.64% | — | |
| 6 | $47.2M | 9.69M | 6.29% | — | |
| 7 | $33.2M | 2.41M | 4.42% | — | |
| 8 | $22.9M | 205.0K | 3.05% | — | |
| 9 | $17.7M | 270.0K | 2.35% | — | |
| 10 | $15.7M | 630.0K | 2.09% | — | |
| 11 | $15.6M | 420.0K | 2.08% | — | |
| 12 | $15M | 934.7K | 1.99% | — | |
| 13 | $14.5M | 169.4K | 1.93% | — | |
| 14 | $13.9M | 713.0K | 1.85% | — | |
| 15 | ? N/A PALISADE BIO INC | $13.9M | 10.28M | 1.85% | — |
| 16 | ? N/A ERASCA INC | $10.6M | 720.0K | 1.41% | — |
| 17 | $9.2M | 1.30M | 1.23% | — | |
| 18 | $7.9M | 249.0K | 1.05% | — | |
| 19 | ? N/A GYRE THERAPEUTICS INC | $7M | 954.4K | 0.93% | — |
| 20 | $6.8M | 574.2K | 0.90% | — |